NEW YORK, April 25, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on TGTX, TRVN, VNDA, and VSTM which can be accessed for free by signing up to www.wallstequities.com/registration. On Tuesday, the NASDAQ Composite ended the day at 7,007.35, down 1.70%; the Dow Jones Industrial
New York headquartered TG Therapeutics Inc.'s stock finished Tuesday's session 2.14% higher at $14.35 with a total trading volume of 1.12 million shares. The stock has gained 38.65% over the past three months and 37.98% in the previous twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 0.07% and 28.25%, respectively. Moreover, shares of TG Therapeutics, which focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the US, have a Relative Strength Index (RSI) of 52.09. Get the full research report on TGTX for free by clicking below at: www.wallstequities.com/registration/?symbol=TGTX
Shares in Chesterbrook, Pennsylvania headquartered Trevena Inc. declined 1.74%, ending yesterday's session at $1.69 with a total trading volume of 301,459 shares. The Company's shares are trading below their 50-day moving average by 3.01%. Moreover, shares of Trevena, which develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions, have an RSI of 49.88. Gain free access to the research report on TRVN at: www.wallstequities.com/registration/?symbol=TRVN
On Tuesday, Washington, the District of Columbia headquartered Vanda Pharmaceuticals Inc.'s stock saw a decline of 2.34%, to close the day at $14.60. A total volume of 356,152 shares was traded. The stock is trading below its 50-day moving average by 14.56%. Additionally, shares of Vanda Pharma, which focuses on the development and commercialization of products for the treatment of central nervous system disorders, have an RSI of 30.48. Register for your free report coverage on VNDA at: www.wallstequities.com/registration/?symbol=VNDA
Shares in Needham, Massachusetts headquartered Verastem Inc. ended the day 0.70% higher at $4.33. A total volume of 859,920 shares was traded, which was above their three months average volume of 820.58 thousand shares. The stock has gained 39.23% in the last month, 24.07% in the previous three months, and 141.90% over the last twelve months. The Company's shares are trading above their 50-day and 200-day moving averages by 28.80% and 18.27%, respectively. Furthermore, shares of Verastem, which focuses on developing and commercializing drugs for the treatment of cancer, have an RSI of 80.68. Get the free research report on VSTM at: www.wallstequities.com/registration/?symbol=VSTM
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/biotech-stocks-research-reports-released-on-tg-therapeutics-trevena-vanda-pharma-and-verastem-300636212.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Birth Control Implant is a long-acting birth control contraceptive inserted into the arm. It is a ...
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...View All